Madrigal Pharmaceuticals (MDGL) said that the European Commission granted conditional marketing authorization for Rezdiffra to treat adults with noncirrhotic metabolic dysfunction-associated steatohepatitis and moderate to advanced liver fibrosis.
Rezdiffra is scheduled to launch in Germany in Q4, followed by other European markets, pending reimbursement agreements, the company said Tuesday in a statement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.